Cartesian Therapeutics
RNAC
94 hedge funds and large institutions have $90.4M invested in Cartesian Therapeutics in 2026 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 12 reducing their positions, and 12 closing their positions.
340% more call options, than puts
Call options by funds: $1.56M | Put options by funds: $355K
267% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 12
160% more capital inflows, than outflows
Capital inflows: $19.1M | Capital outflows: $7.35M
100% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 12
13% more funds holding
Funds holding: 83 → 94 (+11)
2.58% more ownership
Funds ownership: 26.98% → 29.56% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$2.37M |
| 2 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.02M |
| 3 |
BlackRock
New York
|
+$1.63M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.1M |
| 5 |
Two Sigma Investments
New York
|
+$955K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.2M |
| 2 |
Erste Asset Management
Vienna,
Austria
|
-$1.47M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$677K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$624K |
| 5 |
Renaissance Technologies
New York
|
-$348K |
RNAC Hedge Fund Activity: Q2 2026 in Review
94 of the 8,353 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2026, worth a combined $90.4M — up 106% from $43.9M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new RNAC positions and 12 closed out — a net gain of 12 holders — while 44 added to existing stakes and 12 trimmed.
The largest buyer was 683 Capital Management, adding an estimated $2.37M. The largest seller was Fidelity Investments, cutting an estimated $3.2M.
- 94 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2026, up from 83 in Q1 2026.
- Funds reported $90.4M of Cartesian Therapeutics stock for Q2 2026, up 106% quarter-over-quarter.
- 24 funds opened new Cartesian Therapeutics positions in Q2 2026 and 12 closed out, a net change of +12 holders.
- The largest Cartesian Therapeutics buyer in Q2 2026 was 683 Capital Management, an estimated $2.37M added.
- The largest Cartesian Therapeutics seller in Q2 2026 was Fidelity Investments, an estimated $3.2M sold.
Based on aggregated 13F filings for Q2 2026.